ClinicalTrials.gg
Not yet recruitingNCT07585123Updated May 13, 2026

L-PRF in Prevention of ORN and MRONJ Following Tooth Extractions;v3.0

An interventional study of L-PRF and Standard Extraction in Osteoradionecrosis of the Jaw and Medicine Related Osteonecrosis of the Jaw, sponsored by Swansea Bay University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Swansea Bay University Health Board · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Osteonecrosis with a site in United Kingdom — 5 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · United Kingdom.

Planned enrollment
13th of 14
40 · median 206
Started
2026
the only one that year
No phase
6 of 33
1 open now
Primary completion
2027-07
later than 4 of 14 live
Registered
33rd of 33
by date

Among the 33 studies in Osteonecrosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 33rd registered.

Osteonecrosis

287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.

Browse Osteonecrosis studies →

Open to participants now

5 of the 33 studies in Osteonecrosis with a site in United Kingdom are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteonecrosis with a site in United Kingdom, or all of them as a file.
02

Study summary

Osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ) are debilitating complications following dental extractions in patients who have received head and neck radiotherapy or antiresorptive therapy. These conditions are associated with significant morbidity, including persistent pain, poor oral function, and reduced quality of life.

While preventive strategies remain limited, platelet-rich fibrin (L-PRF), an autologous fibrin matrix enriched with growth factors, has shown potential in promoting wound healing and modulating inflammation. This prospective, triple-blind, randomised pilot trial aims to evaluate the effectiveness of L-PRF in enhancing socket healing and reducing the incidence of ORN and MRONJ. Forty patients (20 post-radiotherapy, 20 on antiresorptive agents) undergoing non-surgical dental extractions will be randomised to receive either L-PRF or standard care. The primary outcome is mucosal healing at Day 10 post-extraction, assessed using the Landry wound healing index. Secondary outcomes include the incidence of ORN or MRONJ at extraction sites assessed at 9, 17, 25, and 52 weeks. This study aims to provide early evidence on the clinical utility of L-PRF in preventing osteonecrosis in high-risk patients.

Read the detailed description

Osteoradionecrosis (ORN) is a condition in which necrosis of the jawbone occurs in patients who have previously undergone radiotherapy for head and neck cancer. Medication-Related Osteonecrosis of the Jaw (MRONJ) occurs in patients receiving, or who have received, antiresorptive therapies such as bisphosphonates or denosumab. Both conditions share underlying mechanisms including impaired bone healing, chronic inflammation, and disrupted angiogenesis . Patients in either group face an increased risk of poor healing following tooth extraction, which can result in persistent pain, infection, and progressive jawbone necrosis. These complications profoundly impair patients' abilities to eat and speak, significantly reducing their quality of life.

ORN and MRONJ are extremely difficult to predict, prevent, and manage. Treatment typically requires removal of necrosed bone followed by complex reconstructive procedures that consume significant hospital resources, including materials, staff time, and prolonged hospital stays. Despite these interventions, patients often experience substantial reductions in quality of life. The economic burden on the NHS and responsible trusts is considerable, underscoring the urgent need for improved preventive approaches.

Leukocyte- and platelet- rich fibrin (L-PRF), an autologous leukocyte and platelet concentrate, has demonstrated promising results in promoting soft tissue and bone healing, owing to its angiogenic, anti-inflammatory, and regenerative properties . Its use in dental extractions could mitigate the risk of developing ORN or MRONJ in high-risk populations.

L-PRF is a second-generation platelet concentrate that releases growth factors such as PDGF, TGF-β, and VEGF over an extended period. In vitro studies show that its three-dimensional fibrin matrix continuously releases these factors and cytokines for up to 21 days, which helps regulate inflammation and promote angiogenesis, supporting tissue healing.

L-PRF, a second-generation platelet concentrate, has gained popularity in oral surgery and periodontal procedures (12) with evidence suggesting faster mucosal healing and reduced post-operative complications, because of a slower, continuous release of growth factors when compared to other concentrates in vitro. Furthermore, the leukocytes presented in L-PRF may synthesize several pro- and anti-inflammatory cytokines as well.

However, controlled data on its use specifically for ORN or MRONJ prevention is scarce. Small case series and observational studies suggest improved outcomes, but robust trial data is lacking.

Given the significant morbidity associated with ORN and MRONJ and the lack of proven preventive strategies, evaluating L-PRF in a clinical trial setting is justified. The intervention is autologous and low-risk. Potential benefits include enhanced mucosal healing and reduced incidence of osteonecrosis. Risks are minimal and largely relate to venepuncture or standard surgical procedures. The trial aims to determine feasibility, safety, and early efficacy signals to inform future large-scale trials.

03

Conditions studied

  • Osteoradionecrosis of the Jaw
  • Medicine Related Osteonecrosis of the Jaw

Keywords

  • L-PRF, ORN, MRONJ
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-General Inclusion Criteria (Applies to All Participants)

Age ≥18 years

Requiring extraction of one or more teeth with hopeless prognosis

Capacity to provide

Ability and willingness to attend all scheduled follow-up visits over 12 months

-Post-Radiotherapy Group - Specific Inclusion

Previous radiotherapy to the head and neck region

Documented radiation dose ≥50 Gy

Radiotherapy records (dose, field, date) must be available

-Antiresorptive Group - Specific Inclusion

Current or prior use of antiresorptive agents (e.g. bisphosphonates or denosumab)

Medication history must be available in medical records

Exclusion criteria

Exclusion Criteria:

  • General Exclusion Criteria (Applies to All Participants)

Inability to maintain adequate oral hygiene due to motor disability

Uncontrolled systemic illness (e.g. uncontrolled diabetes)

Use of anticoagulants, , or medications known to impair healing

Requirement for surgical (complex) extractions

Enrolment in another clinical trial

Known allergy to anaesthetic agents, L-PRF components, or antibiotics used in perioperative protocol

Anticipated non-compliance with follow-up

-Post-Radiotherapy Group - Specific Exclusion

Previous or current antiresorptive therapy

History of re-irradiation or radiation dose \<50 Gy

-Antiresorptive Group - Specific Exclusion

History of head and neck radiotherapy

Neoplastic involvement of the jaws

Active untreated oral infection or pathology at time of planned extraction

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    L-PRF Group: Tooth socket will be treated with Platelet-Rich Fibrin (L-PRF)

    Other: L-PRF

  • Placebo comparator
    Control Group

    Other: Standard Extraction

Interventions

  • OtherL-PRF

    L-PRF is made from the patient's own blood and contains natural healing cells and growth factors. It is already used in other areas of dentistry to help wounds heal, but it is not yet clear whether it helps prevent jawbone necrosis in patients with a history of radiotherapy for head and cancers, or in patients taking antiresorptive medications. This study will help us understand whether using L-PRF during extractions makes healing faster and safer and can can prevent or reduce the chance of developing osteoradionecrosis or MRONJ in patients with a history of radiotherapy for head and cancers, or in patients taking antiresorptive medications respectively.

  • OtherStandard Extraction

    No L-PRF will be placed in the post-extraction sockets

06

What researchers measure

Primary outcomes

  1. Mucosal healing of the dental extraction, assessed using the Landry Wound Healing Index.

    Time frame: Day !0

Secondary outcomes

  1. Incidence of ORN and MRONJ at the extraction sites

    Time frame: assessed at 9, 17, 25 weeks and 12 months post-extraction.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

Of 45 interventional studies with no phase under Osteonecrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 91. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 13, 2026
StartEst.
Aug 2, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07585123
Lead sponsor
Swansea Bay University Health Board
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Aug 2, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
May 13, 2026

Study contacts

Partha S Chakraborty
Contact
Partha.Chakraborty@wales.nhs.uk
+44 7867063718
Ketan R Shah, FRCS
study chair · Swansea Bay University Health Board

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion